A 26-Week Treatment, Multicenter, Randomized, Doubleblind, Double Dummy, Placebo-Controlled, Adaptive, Seamless, Parallel-Group Study to Assess the Efficacy,Safety and Tolerability of Two Doses of Indacaterol (Selected From 75, 150, 300 and 600 microg o.d.) in Patients With Chronic Obstructive Pulmonary Disease Using Blinded Formoterol (12 microg b.i.d) and Open Label Tiotropium (18 microg o.d.) as Active Controls

Trial Profile

A 26-Week Treatment, Multicenter, Randomized, Doubleblind, Double Dummy, Placebo-Controlled, Adaptive, Seamless, Parallel-Group Study to Assess the Efficacy,Safety and Tolerability of Two Doses of Indacaterol (Selected From 75, 150, 300 and 600 microg o.d.) in Patients With Chronic Obstructive Pulmonary Disease Using Blinded Formoterol (12 microg b.i.d) and Open Label Tiotropium (18 microg o.d.) as Active Controls

Completed
Phase of Trial: Phase III

Latest Information Update: 03 May 2016

At a glance

  • Drugs Indacaterol (Primary) ; Formoterol; Tiotropium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms INHANCE
  • Sponsors Novartis
  • Most Recent Events

    • 12 May 2010 Results were published in the American Journal of Respiratory and Critical Care Medicine.
    • 02 Nov 2009 Results reported at the 75th Annual Meeting of the American College of Chest Physicians: Chest 2009.
    • 26 Sep 2009 Results presented at the 21st Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top